Know What's Happening in Pharma

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001

GH Research’s inhaled mebufotenin (GH001) demonstrated ultra‑rapid, profound antidepressant effects in a Phase 2b trial for treatment‑resistant depression, with 73% of patients in remission after six months versus ~11% for standard oral therapies. Early‑stage studies in postpartum depression and bipolar disorder showed similarly swift remission, including a ten‑patient postpartum cohort where all achieved remission. GH001’s inhaled delivery yields onset within seconds and a brief 11‑minute psychoactive window, enabling same‑day discharge and potential integration into existing Spravato‑style clinic networks. The company is now preparing a pivotal Phase 3 program while remaining well‑capitalized and publicly traded.